Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.